Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
0.8808
-0.0283 (-3.11%)
Sep 22, 2026, 11:09 AM EDT - Market open
Sunshine Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 35.35 | 36.31 | 34.87 | 24.09 | 4.35 | 0.23 | |
Revenue Growth | -2.74% | 4.11% | 44.75% | 454.42% | 1802.41% | 219.88% |
Cost of Revenue | 24.64 | 24.05 | 24.2 | 15.75 | 2.65 | 0.12 |
Gross Profit | 10.71 | 12.26 | 10.67 | 8.34 | 1.7 | 0.11 |
Selling, General & Admin | 14.81 | 15.33 | 14.94 | 10.83 | 9.48 | 1.87 |
Research & Development | 0.24 | 0.6 | 0.93 | 1.86 | 0.81 | 0.67 |
Other Operating Expenses | 0.51 | 0.47 | 0.39 | 0.29 | 0.06 | - |
Operating Expenses | 15.91 | 16.73 | 16.48 | 13.12 | 10.37 | 2.55 |
Operating Income | -5.2 | -4.48 | -5.81 | -4.79 | -8.67 | -2.44 |
Interest Expense | - | - | -0.01 | -0.14 | -0.04 | -0.33 |
Interest & Investment Income | 0.23 | 0.28 | 0.5 | 0.81 | 0.52 | - |
Currency Exchange Gain (Loss) | 0 | 0 | -0.04 | -0 | -0 | 0 |
EBT Excluding Unusual Items | -4.97 | -4.2 | -5.37 | -4.11 | -8.2 | -2.77 |
Impairment of Goodwill | - | - | - | - | -18.33 | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | - | - | - | - |
Asset Writedown | -0.69 | -1.75 | - | - | - | - |
Legal Settlements | 0.1 | - | - | - | - | - |
Other Unusual Items | - | - | - | - | 0.01 | -9.67 |
Pretax Income | -5.56 | -5.95 | -5.37 | -4.11 | -26.51 | -12.44 |
Income Tax Expense | 0.27 | 0.02 | -0.23 | 0.4 | 0.23 | - |
Earnings From Continuing Operations | -5.83 | -5.98 | -5.13 | -4.51 | -26.74 | -12.44 |
Net Income | -5.83 | -5.98 | -5.13 | -4.51 | -26.74 | -12.44 |
Net Income to Common | -5.83 | -5.98 | -5.13 | -4.51 | -26.74 | -12.44 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 0 | 0 | - | - | - |
Shares Outstanding (Diluted) | 1 | 0 | 0 | - | - | - |
Shares Change | 186.55% | 492.39% | - | - | - | - |
EPS (Basic) | -8.20 | -14.37 | -73.16 | - | - | - |
EPS (Diluted) | -8.20 | -14.37 | -73.16 | - | - | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -5.37 | -5.51 | -14.18 | -8.86 | -5.44 | -1.83 |
Free Cash Flow Per Share | -7.55 | -13.24 | -202.09 | - | - | - |
Gross Margin | 30.30% | 33.76% | 30.59% | 34.61% | 39.04% | 48.42% |
Operating Margin | -14.71% | -12.34% | -16.67% | -19.86% | -199.61% | -1068.24% |
Profit Margin | -16.50% | -16.46% | -14.72% | -18.70% | -615.44% | -5444.41% |
Free Cash Flow Margin | -15.20% | -15.16% | -40.67% | -36.76% | -125.24% | -800.75% |
EBITDA | -4.85 | -4.15 | -5.59 | -4.64 | -8.65 | -2.43 |
EBITDA Margin | -13.72% | -11.42% | -16.02% | -19.24% | -199.03% | - |
D&A For EBITDA | 0.35 | 0.33 | 0.22 | 0.15 | 0.03 | 0.01 |
EBIT | -5.2 | -4.48 | -5.81 | -4.79 | -8.67 | -2.44 |
EBIT Margin | -14.71% | -12.34% | -16.67% | -19.86% | -199.61% | - |